Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204Phone+1 980-442-2000
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Baylor College of MedicineResidency, Internal Medicine, 1996 - 1999
Northwestern University The Feinberg School of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 2022 - 2026
TX State Medical License 1998 - 2026
NC State Medical License 2013 - 2025
Clinical Trials
- A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Start of enrollment: 2014 Mar 28
- A Study of Regorafenib in Advanced Pancreatic Cancer Patients Start of enrollment: 2014 Jun 06
- Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006) Start of enrollment: 2015 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: lung cancer.Edward S Kim
Clinical Advances in Hematology & Oncology. 2023-07-01 - 2 citationsGenomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma.Megan H Jagosky, Colin J Anderson, James T Symanowski, Nury M Steuerwald, Carol J Farhangfar
Cancer Medicine. 2023-03-01 - 16 citationsEfficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).Sai-Hong Ignatius Ou, Makoto Nishio, Myung-Ju Ahn, Tony Mok, Fabrice Barlesi
Journal of Thoracic Oncology. 2022-12-01
Journal Articles
- Stress Hormones Promote EGFR Inhibitor Resistance in NSCLC: Implications for Combinations with Β-blockersHai Tran, Anil K Sood, John V Heymach, Roy Herbst, Lecia V Sequist, Edward S Kim, Science Magazine
Lectures
- Barriers to clinical trial accrual: Clinical trialists' perspectives.2019 ASCO Annual Meeting - 6/1/2019
- Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) that progressed on alectinib ...2019 ASCO Annual Meeting - 6/1/2019
- 94th Annual Meeting of American Radium SocietyAmerican Radium Society, Las Vegas, Nevada - 4/28/2012
Authored Content
- Moving Away (Finally) from Doublet Therapy in Lung Cancer: Immunotherapy and KEYNOTE-189September 2018
Press Mentions
Health Systems Abandon Rigid HierarchiesSeptember 27th, 2024- City of Hope Orange County Appoints Alessio Pigazzi, M.D., Ph.D., as Executive Medical Director, Colorectal SurgeryAugust 20th, 2024
- City of Hope Opens the Most Advanced Comprehensive Cancer Center in Orange County, Calif., Delivering World-Renowned Treatment, Research and Cancer Cures to the Nation’s Sixth Largest CountyJuly 27th, 2022
- Join now to see all
Grant Support
- Early Therpeutics with Phase II EmphasisNIH/NCI2012–2016
- Personalizing NSCLC Therapy: Exploiting KRAS Activated PathwaysNIH/NCI2010–2015
- U10 Full Member Application Affiliated with SWOGNIH/NCI2011–2012
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
